Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The research will test innovative technology that harnesses the body’s intrinsic immune system to transform the treatment of cancer and autoimmune diseases.

© richardlewisohn.co.uk

Dr Michael Dustin has entered into a research collaboration agreement with Cue Biopharma, Inc. a clinical-stage biopharmaceutical company that is engineering a novel class of injectable biological treatments designed to selectively seek out and modify targeted T cells within the body.

Viewed as an exciting next step towards the targeted treatment of both solid and blood cancers, the research collaboration aims to determine the interaction of IL-2, a molecule known to stimulate the immune system with Cue Biopharma's CUE-100 series Immuno-STAT™ (Selective Targeting and Alteration of T cells) Biologics.

"We look forward to working with Cue Biopharma on this innovative and promising new technology," said Michael. "We have long appreciated the effects of IL-2 on the immunological synapse, and this research collaboration will allow us to systematically study effects of natural IL-2 and the engineered Immuno-STAT to define potential features of the Immuno-STAT platform that may be driving the selective and preferential modulation of T cells."

Saso Cemerski, senior director of immuno-oncology discovery and translational immunology at Cue Biopharma said: "Dr. Dustin, the scientific pioneer and founder of the T cell immune synapse field has made seminal observations contributing toward our understanding of the biophysical interactions and signaling pathways that underscore immune cell activation, including the mechanistic underpinnings of T cell recognition of antigens. Our strategic collaboration will exploit the state-of-the art technologies pioneered by Dr. Dustin's lab to elucidate the immune synapse interactions of our IL-2-based CUE-100 series that ultimately result in selective and specific activation of tumor-antigen-specific T cells."